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Abstract: Drugs are bioactive compounds originally discovered from chemical structures present in
both the plant and animal kingdoms. These have the ability to interact with molecules found in our
body, blocking them, activating them, or increasing or decreasing their levels. Their actions have
allowed us to cure diseases and improve our state of health, which has led us to increase the longevity
of our species. Among the molecules with pharmacological activity produced by plants are the
polyphenols. These, due to their molecular structure, as drugs, also have the ability to interact with
molecules in our body, presenting various pharmacological properties. In addition, these compounds
are found in multiple foods in our diet. In this review, we focused on discussing the bioavailability
of these compounds when we ingested them through diet and the specific mechanisms of action of
polyphenols, focusing on studies carried out in vitro, in animals and in humans over the last five
years. Knowing which foods have these pharmacological activities could allow us to prevent and aid
as concomitant treatment against various pathologies.
Keywords: bioavailability; pharmacological; mechanisms of action; biological effects; polyphenol;
in vitro; in vivo; human; concomitant; drugs
1. Introduction
Polyphenols are a group of chemical substances primarily synthesized in plants as
secondary metabolites that are structurally characterized for having one or more hydroxyl
groups (–OH) bound with phenols. All of them are indispensable for physiological func-
tions of vegetables and participate in the defense against stresses such as hydric and light
stress.
They are abundant in nature and extremely diverse in their molecular structure.
They can be found in fruits, leaves, stems, roots, and seeds and to this day, more than
8000 polyphenols have been identified [1]. Therefore, terminology and classification are
complex processes. The chemical structures can be divided based on some differences in
phenolic acids, stilbenes, phenolic alcohols, lignans, and flavonoids [2] (Figure 1). Further-
more, in nature they can be found in their free form (aglycones), bound to other compounds
as sugars (glycosides), or even bound to the extracellular matrix or cell wall.
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Figure 1. Classification of polyphenols.
The major dietary sources are fruits and drinks such as juices, wine, tea, coffee, hot
chocolate, and beer, and in lower quantities in vegetables, legumes, and cereals. The total
ingestion of polyphenols in a standard diet is approximately 1 g/day. Of this, phenolic
acids make up one third of the total, flavonoids make up two thirds, and other variants are
ingested in minor quantities [3].
Studies about bioavailability in humans are still scarce. The concentration in plasma
is rarely found to be above 1 µM after the consumption of 10 to 100 mg of a single phenolic
compound. However, the total phenol concentration in plasma can be augmented depend-
ing on the presence of metabolites formed in the tissue of the organism or the microflora in
the colon. The chemical structure of a polyphenol determines its absorption rate, degree,
and nature of the metabolites that circle in plasma. Therefore, a better understanding of the
absorption and metabolites will help us better understand the bioavailability [3] as they
possess a large number of pharmacological properties.
The health benefits of polyphenols present in our diet has spiked interest among
researchers in the last few years [4–6]. Therefore, the objective of this review is to elucidate
the bioavailability, pharmacological properties, and pathways that polyphenols act upon
to enable us to use these compounds as concomitant treatments or even as prophylactics of
multiple pathologies.
2. Absorption and Metabolism
Due to the molecular structure of polyphenols, their absorption is generally high in
free form thanks to their lipophilic properties, which allow them to pass through plasmatic
membranes by simple diffusion [5]. However, when they form complexes with other
compounds, their absorption changes.
Polyphenols in their free form and in complexes can present changes in the structure
of the digestive tract including on a hepatic level. These changes are observed from the
liberation of the polyphenol, to its union with complex compounds, to the addition of
conjugates, and the generation of metabolites [7]. Additionally, the joint ingestion of other
compounds with polyphenols can affect its absorption: fibers, high fat diets, and the
consumption of alcoholic beverages have an especially high influence. Finally, as will be
discussed in the next sections of this review, polyphenols can be absorbed in the stomach,
the intestine, and colon, or be eliminated through feces.
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2.1. Stomach
Studies performed in an in vitro model of the digestive tract showed the effects diges-
tion exert on the metabolism and absorption of polyphenols. Once ingested, polyphenols
can suffer mechanical disruption, which has been concluded to be a critical point in the lib-
eration of the polyphenol: the chewing, the crushing in the stomach, the gastric movement,
and friction between aliments facilitate the liberation and improve the absorption in the
stomach [8]. Furthermore, it has been shown that an acidic pH does not affect the stability
of the polyphenol and depending on the complex formed, aglycones could be liberated.
On the other hand, mucins liberated during chewing and those present in mucus did not
allow for the gastric absorption nor the liberation of the complex when the polyphenol
presents an affinity toward them.
Some of the simple phenols and flavonoids can be found retained in the fiber of the
extracellular matrix or united with polysaccharides on the cell wall by ester or hydrogenic
bonds. These can be dissolved in alkaline environments such as in the small intestine, but
not in the stomach. Some compounds are changed in the stomach such as procyanidin,
which is degraded to epicatechin in the gastric juice, although this degradation is reduced in
the presence of mucins by union or masking [8]. Additionally, flavonoids such as catechin
and epicatechin are commonly found as aglycones and are easily liberated during gastric
digestion as opposed to flavanols, which are almost exclusively found as β-glucosides, and
are not liberated in the stomach. However, chlorogenic acids such as caffeic acid, ferulic
acid, and p-coumaric acid are hydrolyzed in the stomach and thereby liberate aglycones [8],
which permits their absorption. This has also been proven in in vitro studies that show
how procinadin B1 and antocianines are absorbed at acidic pHs such as that of the stomach
and are not absorbed at alkaline pHs such as that of the intestine [9].
The grand variety of polyphenols and the complexes they form complicate the study
of their absorption on the stomach level. Nonetheless, generally, they can be absorbed in
the stomach in their free forms but not when they form complexes. Even so, the major part
of aglycones will be absorbed on an intestinal level.
2.2. Intestine
Studies have been performed on the metabolism and bioavailability of polyphenols in
the small intestine in rats perfused with polyphenol representing plants including genistein,
hesperetin, and ferulic acid [10].
The intestinal absorption of these flavonoids can be achieved through passive dif-
fusion or co-transportation with sodium. The perfusion of various polyphenols did not
affect the absorption, which suggests that the transport mechanisms cannot be saturated.
Additionally, the intestinal cells have the capacity to generate phenolic complexes, which
they can secrete to the lumen, thereby reducing the net absorption [10]. Previous studies
have suggested that the active secretion of these complexes could be regulated by the
MPR-2 and/or the P-glycoprotein. The MRP-2 is an ATP-dependent protein in charge
of the detoxification of organic compounds bound to glutathione, glucuronidases, and
sulfatases [11], and are mainly expressed in the liver or intestine.
It is important to keep in mind that the secretion rates of these complexes returning to
the lumen are notably different depending on the polyphenol. For ferulic acid, it was low
compared to the two flavonoids, which suggests a higher bioavailability for the latter. The
secretion of these compounds combined can reach a saturation point, as the administration
of higher quantities of polyphenols did not lead to a proportional increase in secretion.
Other polyphenols such as genistein and hesperetin suffer hepatic conjugation and were
secreted in bile once absorbed, which diminishes their bioavailability [10]. Furthermore, it
has been observed how the intake of cranberry juice in humans shows different absorption
patterns between individuals. Therefore, it must be taken into account that the absorption
at the intestinal level is also determined by the patterns of the microbiome, which differs
between each individual [12].
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In conclusion, intestinal absorption, splanchnic metabolism, and biliary and intestinal
secretion of polyphenols govern the majority of their bioavailability.
2.3. Colon
The polyphenols that are not absorbed in the stomach or small intestine can be
metabolized by the intestinal microbiota and reach the colon where they can be absorbed
or eliminated through feces.
The colon contains 1012 microorganisms/cm3 and therefore presents an immense
catalytic and hydrolytic potential. Deconjugations happen easily, for example, quercetin-3-
orham glucoside and quercetin-3-O-ramnoside cannot be hydrolyzed by human endoge-
nous enzymes but are easily hydrolyzed in the microflora by organisms such as Bacteroides
distasonis (α-ramnosidase and β-glucosidase), B. uniformis (β-glucosidase), and B. ovatus
(β-glucosidase) [13].
As opposed to the enzymes in human tissue, the microflora of the colon can catalyze
the decomposition of polyphenols to simple compounds such as phenolic acids. Other
organisms such as enterococcus casseliflavus metabolize half of the sugar of quercetine-
3-o-glucoside to make acetate and lactatebut does not metabolize aglycone. Studies
in vitro have shown that when quercetin-3-O-ramnoside was incubated anaerobically
with human intestinal bacteria, it was metabolized by 3,4-dihydroxilphenylacetic and
4-hydroxylbencoic acid. In humans, it has been observed how aglycone is transformed by
the microflora of the colon to 3-hydrocylphenilacetic, 3-methoxi-4-hydroxyphenilacetic, 3,4-
dihydroxylphenilacetic, 3,4-dihydroxitoluen, and b-m-hydroxyphenilhydrpacrilic acid [14].
A polymer of procyanidin also experienced degradation by the microflora due to the
phenolic metabolic acids that are later absorbed in the colon [15]. The hydroxycinnamic
acids connected to the cell walls of plans are not liberated by endogenous mammal en-
zymes and require enzymes such as xylanase and esterase from the colon microflora to be
liberated [16].
Despite the great variety of polyphenols and metabolites they can form in the mi-
croflora of the colon, we have only cited a few examples in this revision. It is, however,
clear that the polyphenols that cannot be absorbed or metabolized and reach the colon can,
due to its microflora, experiment an active metabolism, thereby liberating aglycones and
their derived metabolites, which can be further absorbed and enter the blood stream. There-
fore, this pathway cannot be discarded when studying the pharmacological properties of
polyphenols. Figure 2 summarizes the absorption and metabolism of polyphenols.
Figure 2. Absorption and metabolism of polyphenols.
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3. Bioavailability
Although we have already commented on bioavailability in the previous paragraphs,
due to its complexity, we will proceed to summarize the known concepts. The chemical
properties of polyphenols depend on their bioavailability, which can be measured indirectly
by studying the antioxidant capacity in plasma or by directly measuring the quantity of
polyphenol in plasma after the consumption of a compound in its pure form or foods
containing the compound of interest.
Studies in humans show that the intact quantities present in urine vary between 0.3
and 1.4% of phenolic compounds such as routine or glucoside of quercetin to 3–26% in
catechins from green tea, soy isoflavones, citric flavanones, and anthocyanidins from red
wine. However, the major part of the polyphenols ingested (75−99%) are not found in
urine, implicating that they are not absorbed by the intestinal barrier nor metabolized by
the microflora [3].
Studies have shown that intact flavonoid concentrations are rarely found to exceed
1 µM by a balanced diet. These concentrations are usually achieved 1–2 h post ingestion [17],
except for the polyphenols that are absorbed only after their partial degradation by the
colon microflora such as the routine liberated by quercetin, which reach peak plasmatic
concentrations 7 h post ingestion [18]. Additionally, some compounds take up to one day
for the body to eliminate such as equol, enterodiol, and enterolactone [19]. For example,
after the consumption of flaxseed, plasma lignan concentrations did not peak until 9 h and
were maintained for 24 h after intake, suggesting that the metabolism, absorption, and
elimination of lignans from flaxseed takes longer than that of soy isoflavones.
As we have commented previously, the polyphenols present in food and drinks can
be found naturally both in their free form and in a large variety of complexes. Additionally,
they can be transformed all the way through the digestive tract from the mouth to the
colon. They can be liberated from their conjunctions, re-conjugate in the intestine or
liver, become metabolized by the microflora after being absorbed by the digestive tract,
unite with plasmatic proteins, and are incorporated into adipose tissue. Due to the many
possible structures and interactions, the bioavailability of polyphenols is extremely diverse.
Understanding these processes can help us predict how, when, and what to ingest to obtain
maximum efficiency from the beneficial and pharmacological properties, which we will
describe in the following sections.
Experimental Studies
In the following paragraphs, we outline the most relevant studies performed in the
last five years regarding polyphenols and their potential pharmacological effects (see
Supplementary Material for search criteria and methodology).
4. In Vitro Studies
4.1. Cardiovascular Disease
Cardiovascular disease is the leading cause of morbidity and mortality, in 2015, the
World Health Organization estimated that cardiovascular diseases accounted for over 30%
of deaths worldwide [20].
It is commonly known that saturated free fatty acids lead to endothelial injury and
cardiovascular complications [4]. A study by Song, J. et al. showed that 10, 50, and 100 µM
resveratrol prevented palmitic acid-induced intracellular ROS by autophagy regulation
through the AMPK-mTOR pathway, thereby providing cardiac protection in metabolic
syndrome in human aortic endothelial cells [21]. Additionally, the resveratrol dimers ε-
viniferin and pallidol at 10 and 50 µM exerted potential anti-angiogenic effects by enhancing
eNOS activation via Akt phosphorylation and inhibition of the vascular endothelial growth
factor receptor 2-induced PLCγ1 phosphorylation in human umbilical vein endothelial
cells [22]. In another study on endothelial cells Xu, Y. et al. showed how tannic acid at
10 and 20µM induces KLF2 expression and attenuates TNFα-induced inflammation and
monocyte cell adhesion [23].
Biomedicines 2021, 9, 1074 6 of 26
The benefits of tea polyphenols have been widely studied both in vitro and in vivo. A
recent study showed how pretreatment with1, 5, 10 µM epigallocatechin-3-gallate (EGCG),
the major polyphenol found in green tea, improved cell survival after exposure to H2O2
in endothelial cells by inducing autophagy and inhibiting apoptosis by downregulating
the PI3K-AKT-mTOR signaling pathway [24]. Additionally, 10, 30, and 50 µM of EGCG
in neonatal rat cardiomyocytes have been shown to inhibit pressure overload-induced
cardiac hypertrophy by upregulating the PSMB5/Nmnat2/SIRT6-dependent signaling
pathway [25].
Moreover, medicinal plant extracts have long been used, especially in oriental cultures.
Decoctions of 1 g/L teabag containing S. cumini and P. mauritianum have been shown to
decrease ox-LDL uptake by more than 70%, while inhibiting the NF-κB pathway in the
presence of pro-inflammatory concentrations of E. coli lipopolysaccharides in RAW 264.7
murine macrophages [26]. Furthermore, salvianolic acid A, a natural polyphenol extract
widely used as traditional medicine in China for its cardioprotective functions, was recently
shown to protect against lipotoxicity-induced myocardial damage at 5, 10, 20, and 40 µM
through a TLR4/MAPKs signaling pathways in H9c2 cells [27].
4.2. Diabetes
There are few in vitro studies on the effects of polyphenols and their influence on
diabetes type I. However, one study by Pham Hua et al. showed that a 4 µM tan-
nic acid/poly(N-vinylpyrrolidone) multilayer coating attenuated the synthesis of pro-
inflammatory cytokines and T cell effector responses involved in autoimmunity in vitro,
thereby modulating the innate and adaptive immune response, and providing potential
protective effects against type 1 diabetes [28].
Studies on type 2 diabetes, on the other hand, are more common. One study showed
that polyphenolic extracts from Indian ginger at 6.25 µg/mL increased insulin stimulated
glucose uptake in C2C12 cells by inhibiting α–amylase and α–glucosidase, decreasing
glycation, and increasing GLUT4 expression [29]. Similar results were found in a recent
study of the effects of 30 and 90 µg/mL of the polyphenol-rich Terminalia phaeocarpa,
which was found to inhibit pancreatic lipase, α-amylase, and α-glucosidase, TNF-α, IL-1β,
and CCL-2 expression in LPS-treated THP-1 cells [30]. A study by Vlavcheski et al. also
showed how 5 µM rosmarinic acid increased glucose uptake to levels comparable to insulin
and metformin treatments through AMPK phosphorylation in L6 rat muscle cells [31].
Furthermore, ellagic acid at 50 µM, 10 and 20 µM punicalagin, and particularly 50 µM
of urolithin A have been shown to prevent metabolic diseases like obesity and diabetes
by inhibiting lipase, α-glucosidase, and dipeptidyl peptidase-4 activity, and by reducing
triglyceride accumulation and adipocyte formation through reducing adiponectin, PPARγ,
GLUT4, and FABP4 expression in 3T3-L1 adipocytes [32].
4.3. Obesity
Obesity is rising worldwide and is mainly attributed to changes in lifestyle including
overconsumption of food and decreased physical activity. Studies of plant extracts and
compounds show that polyphenols can play a beneficial role in the prevention of obesity
by reducing cholesterol levels, fatty acid synthesis, triglyceride formation, and inhibiting
genes involved in adipocyte differentiation and triglyceride accumulation [33].
Several studies have shown that ginger enhances thermogenesis, energy expenditure,
and provides lipid metabolism regulation, thereby providing potential therapeutic effects
on obesity. The polyphenol 6-gingerol improves mitochondrial respiration and energy
metabolism by increasing the uncoupled oxygen consumption rate of protons leaked and
upregulating mitochondrial biogenesis markers through the AMPK signaling pathway in 3T3-
L1 and HepG2 cells at 47.81 ± 0.62 mg/g and 10 to 200 µM quantities, respectively [34,35].
Similar results were found when analyzing the effects of ginseng, which was also found
to exert anti-obesity effects by inducing adipocyte browning through AMPK activation at
25, 50, and 100 µg/mL in 3T3-L1 and primary white adipocytes [36]. Additionally, anti-
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obesity properties of phenolic compounds of canola have been studied using adipogenic
differentiation inhibition of a murine mesenchymal stem cell line (C3H10T1/2). Significant
adipogenesis and pancreatic lipase inhibitory activities were found after treatment of 2–3
mg/mL canola meal extract through the downregulation of the peroxisome proliferator-
activated receptor gamma (PPARγ) signaling pathway [37].
In 2019, Mao et al. found that the 10 and 20 µM EGCG exerted suppressive effects
on lipid accumulation and proinflammatory cytokines by inhibiting the JAK2/STAT3
signaling pathway in palmitic acid-stimulated BV-2 microglia [38]. Furthermore, 2 and
10 µM curcumin have been found to repress adipogenic differentiation through the Wnt
signaling pathway in 3T3-L1 cells [39]. Finally, 50 µM of piceatannol, a lesser studied
analogue of resveratrol, has been proven to have antiadipogenic properties by limiting lipid
synthesis and accumulation in hMSC-derived adipocytes, lowering glucose transport into
adipocytes and inhibiting the PPARγ pathway, and thereby can be used in the treatment of
metabolic complications associated with obesity [40].
4.4. Digestive Diseases
The intestinal epithelium is in direct contact with a variety of nutrients, microbes, and
exogenous toxins, offering both a barrier and absorptive functions in the intestine [41].
Punicalagin, a major polyphenol abundant in pomegranate fruit, has been found to increase
cell viability at 40 µM in small intestine epithelial rat IEC-6 cells in response to heat shock
via the PI3K/Akt pathway, thereby preserving the integrity of the intestinal epithelium [41].
Lipid metabolism disorders in liver often lead to nonalcoholic fatty liver diseases
(NAFLD), which is a common chronic liver disease connected with the accumulated uptake
of free fatty acids. A study found that 200 µM cichoric acid limits lipid accumulation
in HepG2 cells by enhancing the Akt/GSK3β signaling pathway and modulating the
downstream expressions related to lipid metabolism, indicating that cichoric acid can be
useful as a natural NAFLD modulator [42].
The beneficial health effects of walnut have long been attributed to its rich n-3 polyun-
saturated fatty acid character and anti-oxidative and anti-inflammatory properties. In a
study by Park et al., 10 or 20 µg/mL walnut polyphenol extracts were found to suppress
H. pylori infection induced phosphorylation of STAT3 in a PPAR-γ dependent manner in
RGM-1 gastric mucosal cells, thereby providing protection against gastric pathologies such
as chronic atrophic gastritis and gastric cancer [43]. Moreover, Hossen et al. found that
50 µM resveratrol extract exerted anti-inflammatory effects on lipopolysaccharide-treated
macrophages by inhibiting the signaling events upstream of NF-κB translocation such as
phosphorylation of AKT and the formation of PDK1-AKT signaling complexes [44].
To this day, the only treatment for celiac disease is a life-long, strict gluten-free diet,
however, peptide antibodies have become gradually more important in the diagnostic
work-up of celiac disease [45]. In one study, 80 µM of procyanidins were shown to reduce
the celiac disease bioactive peptide 32-mer translocation in Caco-2 cells, thus modulating
the transepithelial transport of celiac disease bioactive peptides [46].
4.5. Neurodegenerative Disease
The health effects of the consumption of polyphenols through a diet rich in fruits
and vegetables and their impact on neurodegenerative diseases have been extensively
studied. Ribes diacanthum Pall, a native Mongolian medicinal plant, has been reported to
show antioxidant activities due to its polyphenolic content, exert cytoprotective effects
at 10, 25, and 50 µg/mL in mouse hippocampal neuronal HT-22 cells by regulating the
expression of antioxidant enzymes and activating the BDNF/TrkB pathway [47]. In another
study where PC12 cells were induced to apoptosis, 10 µM of Honokiol, a magnolia derived
polyphenol, was shown to promote neuroprotective effects by increasing glutathione levels,
upregulating cytoprotective proteins, and promoting transcription factor Nrf2 nuclear
translocation and activation [48].
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One study on the bioavailability of 19 plant metabolites and their effects on oxidative
stress related neurodegeneration found that 10 µM 3,4-dihydroxyphenylpropionic acid,
3,4-dihydroxyphenylacetic acid, gallic acid, ellagic acid, and urolithins decreased oxidative
stress-induced apoptosis by preventing caspase-3 activation through the mitochondrial
apoptotic pathway in SH-SY5Y cells [49].
Neurodegenerative diseases are typically characterized by the loss of neurons due
to several pathological mechanisms or processes such as glutamate excitotoxicity, oxida-
tive stress, and abnormal apoptosis [50]. Resveratrol is well known for its antioxidative
properties, however, a study performed by Wang, W. et al. demonstrated that 50 mg/mL
resveratrol can exert additional protective effects against neurodegeneration by inhibiting
glutamate-induced apoptosis in primary hippocampal neurons by enhancing Bcl-2 and
decreasing Bax and Caspase-3 expression through the PI3K/AKT/mTOR pathway [51].
Furthermore, 100 µM resveratrol has been found to exert neuroprotective effects by com-
batting glutathione depletion through the HO-1 pathway in C6 astroglial cells [52].
4.6. Cancer
Many interesting findings have also been published regarding the protective bene-
fits of polyphenols against cancer. Studies have shown how treatment with 140 µM tea
polyphenols induces mitochondrial-mediated apoptosis by activating the caspase-3 and
PARP apoptotic cascade in human gallbladder cancer cells [53], 0.5–5 µg/mL of EGCG
reduces the cell viability and increases the apoptosis rate of myeloid-derived suppressor
cells, mainly through the Arg-1/iNOS/Nox2/NF-κB/STAT3 signaling pathway [54], and
15 µM EGCG inhibits Excision Repair Cross-Complementation Group1/Xeroderma Pig-
mentosum group F, thereby inhibiting DNA repair and enhancing cisplatin sensitivity
in human lung cancer cells [55]. A total of 0.1–1 mM catechin with lysine has also been
proven to have antimigratory effects in breast, pancreatic, and colorectal cell lines through
JAK2/STAT3 and Wnt pathway inhibition [56]. Additionally, 500 µM of Annurca apple
polyphenol extracted catechin has been shown to be a potent pro-oxidant and antiprolif-
erative agent able to downregulate the ERK1/2 pathway, leading to cell cycle inhibition
and apoptosis [57]. The flavonoid quercetin, a polyphenol abundant in the Mediterranean
diet, also has apoptotic effects through the regulation of the phosphatidylinositol 3-kinase
(PI3K)/protein kinase B (AKT)/forkhead box protein O 1 (FOXO1) pathway in A549 cells
at 160 µg/mL [58]. Furthermore, Ruzzolini, J. et al. showed that oleuropein, a glycoside
found in olive leaves at 250 µM affected cell proliferation and induced the downregulation
of the pAKT/pS6 pathway in Human BRAF Melanoma Cells [59].
As seen, polyphenols have the ability to exert several beneficial effects in vitro. Figure 3
summarizes the effects discussed in this review.
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Figure 3. Effects of polyphenols found in animal models and in vitro studies.
5. Animal Models
5.1. Cardiovascular Disease
Cardiovascular diseases are arguably the most important comorbidities in chronic
obstructive pulmonary disease [60]. Curcumin, a dietary polyphenol found in turmeric,
has been found to have therapeutic benefits in chronic obstructive pulmonary disease by
inhibiting NF-κB. In a recent study, administration of 2.5, 5, and 7.5 µM and 100 mg/kg−1
curcumin attenuated cigarette smoke-induced inflammation both in vitro and in vivo by
modulating the PPARγ-NF-κB pathway [61]. Furthermore, curcumin at concentrations
of 25 mg/kg/day has been found to reduce serum lipid levels, inflammation damage
in heart, lungs, and kidneys, and decrease the formation of atherosclerotic plaque in
the aorta through HMGB1-TLRS-NF-κB signaling pathway-related proteins in a high
fat diet fed mice [62]. Protocatechuic acid has also been reported for its cardiovascular-
protective effects. A study showed how 200 mg/kg/day for 12 weeks significantly im-
proved endothelium-dependent IGF-1-induced vasorelaxation by enhancing the activity
PI3K/NOS/NO pathway in aged hypertensive rats administered [63].
Additionally, mangiferin, a polyphenol found in mango and papaya, has been found
to decrease plasma lipids and inflammatory levels in mice with high fat diet-induced
vascular injury through the PTEN/Akt/eNOS signaling pathway at 20 µM [64]. Moreover,
in an in vivo myocardial ischemia rat model, 200 mg/kg lychee extract was found to exert
myocardial protection through bcl-2/bax gene expression [65].
5.2. Diabetes Mellitus
Numerous studies have been performed to analyze the effects of polyphenols on
diabetes. Regarding type 1 diabetes mellitus, a study was performed in streptozotocin-
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induced diabetic mice to evaluate the effects of 10–250 mg/kg (-)-epicatechin-3-O-β-D-
allopyranoside from Davallia formosana (BB) over a 28-day period. BB was found to
increase the expression of fatty acid oxidation enzymes such as PPARα and carnitine palmi-
toyl transferase 1a and lower mRNA levels of SREBP1c and AFABP2, thereby reducing
plasma triglyceride levels [66]. Caesalpinia bonduc, traditionally used in herbal medicines
for the treatment of a wide range of diseases, has been shown to restore insulin, glucose,
leptin, and amylin as well as carbohydrate metabolizing enzymes after eight weeks of 250
and 500 mg/kg administration in alloxanized diabetic rats by inhibiting the JNK signaling
pathway [67].
To study the effects of gallic acid on type 2 diabetes, a combined mouse model of a
high fat diet induced obesity and low dose streptozotocin induced hyperglycemia was
used as it mimics the pathological condition. The administration of 150 mg/kg gallic acid
was shown to alleviate lipid accumulation through the upregulation of β-oxidation and
ketogenesis [68]. Another study showed that the administration of 50 mg/kg ellagic acid
for 45 days mitigated insulin resistance in T2DM rats by reducing HIF-α and upregulation
of NRF2 by enhancing the Akt signaling pathway [69]. Muscle loss is highly associated
with diabetes as elevated lipid metabolites impair myogenesis. Dietary supplementation
of 20 and 200 mg/kg oligonol for 10 weeks has been found to decrease lipid levels and
attenuate muscle loss by downregulating the MAFbx/atrogin-1 pathway and upregulation
the SIRT1/AMPKα pathway in diabetic db/db mice [70].
5.3. Obesity
In an in vivo study in old mice, 2.3µg/kg/day resveratrol supplementation for two
days was shown to activate fatty acid degradation and inhibit their synthesis through
activation of the AMPK pathway. The respiratory quotient was also found to be lowered
due to fatty acid transport from white adipose tissue into the mitochondria and subsequent
β-oxidation in muscles and liver, determined by increased expression and phosphoryla-
tion of the enzymes involved in lipid catabolism such as acyl-CoA synthetase, carnitine
acylcarnitine translocase, and carnitine palmitoyl transferase 1 [71]. Similarly, another
study reported that 1000 mg of chokeberry polyphenols extract/kg improved dyslipidemia
and lipid metabolism and lipogenesis mediated through the FXR and TGR-5 signaling
pathway on high fat diet-fed rats [72]. Furthermore, 100 mg/kg cinnamon polyphenol
extracts have been found to decrease body weight and visceral fat as well as improve lipid
profile and MDA concentrations via the PPAR-α and Nrf2 pathways in rats fed a high fat
diet [73]. The administration of curcumin also reduces body weight and fat accumulation,
lowers blood insulin levels, and preserves islet integrity through the downregulation of
TXNIP transcription factors, as reported in a study on mice administered a high fat high
sugar diet supplemented with 0.4% (w/w) curcumin [74]. Additionally, the interaction
between prebiotics and probiotics might exert synergistic benefits on health. Cho et al.
investigated the combined effects of 10% polyphenol-rich wine-grape seed flower and
lactic acid bacteria from kefir on high-fat induced obese mice. They reported that this
combination exerted the highest improvements on body weight gain, plasma insulin, and
cholesterol concentrations compared to their administration separately and the control [75].
5.4. Neurodegenerative Diseases
Coffee polyphenols such as chlorogenic acid halts neurodegeneration and provides
neuroprotection against Parkinson’s disease by blocking the dopaminergic neuronal toxin
6-OHDA and combinatorial α-synucleinopathy through the Akt1-CREB-RNF146 pathway
at 1 and 10 µM [76]. Moreover, 5-caffeoylquinic acid, another polyphenol present in
coffee, exerts neuroprotective effects by reducing Aβ plaque formation and neuronal
loss and ameliorating cognitive decline by modulating the Aβ clearance pathways when
administered with a high fat diet at 0.8% (w/w) compared to the control [77]. Similarly, 0.5%
rosmarinic acid has been found to suppress Aβ accumulation and increase monoamines
such as norepinephrine, 3,4-dihydroxyphenylacetic acid, dopamine, and levodopa in mice
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by enhancing the dopamine signaling pathway [78]. Resveratrol has also been found to
exhibit neuroprotective effects against Parkinson’s disease. However, due to its water
solubility, its oral bioavailability reduces and therefore demonstrates low efficacy in the
blood and brain. In a recent study, a nanocrystal formulation of resveratrol was developed
to enhance its oral bioavailability and delivery to the brain. They reported higher plasma
and brain concentrations, attenuated dopamine deficiency, and notable improvements in
behavior. Immunoblot analysis revealed that these benefits are mediated by the Akt/Gsk3β
signaling pathway [79].
Although spinal cord ischemic stroke is not considered a neurodegenerative disease, it
is known to produce detrimental effects on neuronal function, leading to the development
of neurodegenerative diseases. One of the important pathophysiological effects of ischemic
stroke is apoptosis. Intraperitoneal injection of resveratrol at 30 mg/kg has been found to
provide neuroprotective effects against cerebral ischemic injury by attenuating neuronal
apoptosis by upregulation of the PI3K/Akt/mTOR pathway through the activation of the
JAK2/STAT3 pathway [80]. Additionally, rats treated with 10 mg/kg resveratrol showed
improvements in injury percussions after spinal cord ischemia-reperfusion injury by its
ability to suppress the activation of the iNOS/p38MAPK pathway [81]. Ellagic acid has also
been shown to protect against ischemia by increasing the proliferation of NSCs through the
Wnt/β-catenin signaling pathway, thereby providing protection against nerve dysfunction
at concentrations of 1.0, 3.0, and 9.0 µg/mL [82].
5.5. Digestive Diseases
NAFLD is associated with hepatic insulin resistance (IR). Sub-chronic pretreatment of
20 mg/kg resveratrol in Winstar rats fed a high fat diet has been found to prevent early
hepatic IR through inhibiting PKC/JNK activation, thereby reducing the expression of
acyl-CoA:glycerol-sn-3-phosphate acyltransferase and diacylglycerol:acyl-CoA acyltrans-
ferase, two critical enzymes in the glycerol-3-phosphate pathway for de novo triglycerides
synthesis [83]. Autophagy induced by the SIRT1-FOXO signaling pathway has recently
been shown to be a critical protective mechanism against NAFLD development. Ding
et al. found that 200 mg/kg bw resveratrol combined with a caloric restriction of 30%
increased the expression of SIRT1 and autophagy markers while decreasing ER stress
markers in the liver, partially preventing hepatic steatosis and hepatocyte ballooning, and
alleviating lipid metabolism disorder in rats fed a high fat diet [84]. Similarly, 100 mg/kg
curcumin attenuates hepatic steatosis and reversed the abnormalities of serum biochemical
parameters of non-alcoholic fatty liver disease induced by a high-fat and high-fructose diet
in C57BL/6 mice via the Nrf2-FXR-LXR pathway [85].
Moringa oleifera Lam. is an essential herb used in the treatment of various diseases
such as inflammation, diabetes, and high blood pressure. Quantities of 50 mg/kg and
200 mg/kg of M. oleifera polyphenol extract, rich in quercetin, kaempferitrin, chlorogenic
acid, luteolin, and rutin, has been found to alleviate the symptoms of dextran sulfate
sodium-induced colitis by the downregulation of NF-κB p65 and p-IκBα [86].
5.6. Cancer
Red wine consists of a large number of compounds including resveratrol, which
exhibits chemopreventative and therapeutic effects. However, a recent study reported
that another polyphenolic red wine component, ellagic acid, inhibited lung cancer cell
proliferation at an efficacy approximately equal to that of resveratrol at concentrations
higher than 25 µM by inactivation of the mechanistic target of rapamycin signaling pathway
and significant inhibition of tumor growth with the suppression of CIP2A levels and
increased autophagy in tumor-bearing mice [87]. A quantity of 20 µM of ellagic acid
has also been found to suppress lung metastasis and exerts beneficial effects against
endometrial cancer in BALB/c nude mice via the PI3K signaling pathway [88].
As mentioned earlier, the tea polyphenol EGCG is widely known for its anti-inflammatory
effects. In a recent study, 80 µM EGCG was shown to inhibit lung cancer cell proliferation
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by suppressing NF-kB signaling in a mouse xenograft model, which was potentiated with
coadministration by the NF-κB inhibitor BAY11-7082. The scientists of this study concluded
that this synergistic effect of low dose EGCG at 2.5 or 5 µM with BAY11-7082 may serve
as a novel therapeutic strategy for lung cancer [89]. In another study, mango polyphenols
(0.8 mg gallic acid equivalents per day) and pyrogallol (0.2 mg/day) administered for
four weeks to mice xenografted with MCF10DCIS.com cells inhibited proliferation of
breast cancer cells through ROS-dependent upregulation of AMPK and downregulation of
the AKT/mTOR pathway [90]. Phenolic extract from olive trees also decreased HCT116
and HCT8 colon cancer cell viability by inducing the mitochondrial apoptotic pathway
when treated with 20 µg/mL [91]. Finally, in another study on a mouse xenograft model,
curcumin treatment was shown to inhibit hepatocellular carcinoma proliferation in vivo
at concentrations of 50 and 100 mg/kg by decreasing VEGF expression and PI3K/AKT
signaling in a mouse xenograft model [92].
Similar to the findings in in vitro studies, polyphenols have also been found to exert




In clinical trials aimed at attributing the therapeutic effect of polyphenols in cardiovas-
cular diseases, the changes in arterial blood pressure (BP), lipid metabolism, endothelial
function, and other risk factors were tested as the endpoint results of various interventions.
Significant reduction of diastolic BP and the decrease in systolic BP were confirmed
in participants with stage 1 or 2 hypertension and metabolic syndrome after 28-day treat-
ment with supplements containing several phenolic compounds (grape seed and skin
330 mg, green tea extracts 100 mg, quercetin dehydrate 50 mg, resveratrol 60 mg, and
other phytochemicals 10 mg a day). The complementary analysis allowed researchers to
assume that the observed effect on BP could be related to an increase in nitric oxide (NO)
bioavailability [93]. Results in a crossover trial in Finland showed a statistically signifi-
cant diastolic BP lowering effect and decrease in IL-10 and TNF-α after the eight week
consumption of Aronia mitschurinii products with the total mean intake of 2194 mg/day
chokeberry polyphenols [94]. A randomized, placebo-controlled study involving partici-
pants with stage 1 hypertension tested the potential hypotensive effect of low molecular
weight oligomeric procyanidin extract (150 mg/day) made of French Maritime Pine bark.
When BP changes were compared to those of the placebo group, significant lowering of
systolic BP in the result of 5-week treatment was confirmed only in female participants.
The supplementation of procyanidins was also associated with beneficial changes in lipid
profile of a statistically significant reduction in the Apo B-100/Apo A-1 ratio and increase in
high-density lipoprotein-cholesterol [95]. Additionally, favorable effects on BP and plasma
lipids resulting from phenolic-rich olive leaf extract intake (136.2 mg oleuropein and 6.4 mg
hydroxytyrosol daily) was confirmed in a randomized trial. After a 6-week treatment,
both systolic and diastolic BP, total cholesterol (TC), low-density lipoprotein cholesterol
(LDL-C), and triglycerides were statistically significantly lowered in pre-hypertensive
participants when compared with values in the control group [96]. To analyze whether a
combined polyphenol preparation could attenuate cardiovascular disease risks in healthy
adults, citrus, bitter orange, grapefruit, and olive polyphenol compounds in a daily dose of
250–300 mg flavanone-glycosides, 175–200 mg of flavones, and 85–90 mg secoiriodids and
phenolics were administered. After eight-weeks of treatment, a decrease in mean values
of diastolic BP, TC, LDL-C, LDL-oxidase, IL-6, and protein carbonyl as well as increased
flow-mediated vasodilation and reduced/oxidized glutathione ratio in the active product
group were statistically significant compared to the placebo group [97]. A study on the
intake of a polyphenol-rich (around 210 mg/day) cranberry beverage by overweight or
obese adults with CVD risk led to statistically significant changes in lipid metabolism,
pro-inflammatory markers, and modulators of vascular tone in the intervention group
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compared to the control. After eight-weeks, increased HDL-H and lowered CRP were
shown, whereas the beneficial effects of augmented reduced/oxidized glutathione ratio,
plasma endothelin-1, and NO levels were confirmed only at the baseline week [98]. In
patients with peripheral arterial disease of lower limbs and intermittent claudication, a
24-week treatment with 2 g/day of the polyphenolic extract of Annurca apple signifi-
cantly increased walking autonomy and improved hemodynamic parameters such as an
ankle-brachial index and acceleration time to peak systolic velocity. At the same time,
no significant differences were revealed in the placebo group. Additionally, self-reported
symptoms like paresthesia, cold limbs, and cold toes caused by vascular abnormalities in
the treatment group diminished or disappeared, whereas no similar changes were observed
in the placebo group [99]. Figure 4 summarizes the effects of polyphenols on cardiovascular
disease outlined in this review.
Figure 4. Effects of polyphenols on cardiovascular disease in human studies.
6.2. Diabetes Mellitus
The potential of natural polyphenols to ameliorate glucose metabolism and decrease
complications of diabetes mellitus were evaluated in various clinical studies involving
patients with type 2 diabetes mellitus (T2DM) or non-diabetic adults with risk factors for
T2DM such as overweight, prediabetes, low physical activity, and family history. Usually,
the parameters of inflammation, glucose and lipid metabolism, and antioxidant status
in participants are measured as indicators of the effect of polyphenol treatment. In a
double-blind, randomized, placebo-controlled trial, the intake of 40 or 500 mg/day of
resveratrol was tested for anti-inflammatory effects and improvement in total antioxidant
status (TAS) in T2DM patients. After six months of treatment, the C-reactive protein (CRP)
concentration decreased more in the high dose resveratrol group than in the low dose
group, although none of the results were statistically significant compared to those of the
placebo group. A more prominent decrease in CRP from the baseline was associated with
lower diabetes duration and some additional modifying factors [100]. The concentration of
an acute-phase protein, pentraxin, whose role in inflammatory responses remains unclear,
was increased after intervention, meanwhile significant improvement of TAS was observed
after supplementation with resveratrol [101]. To prove the anti-inflammatory and lipid
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regulatory activity of curcumin, which could be used to prevent complications of diabetes,
a study tested inflammatory markers, lipid profile, and serum adiponectin changes in
T2DM patients after treatment. Results confirmed that the intake of 1500 mg/day curcumin
for ten weeks significantly decreased high-sensitivity CRP and triglyceride levels, and
increased anti-inflammatory cytokines and serum adiponectin levels compared to the
placebo [102]. The beneficial effect of apple polyphenols on glucose homeostasis was
observed in a trial conducted in Japan. In non-diabetic adults with high-normal and
borderline plasma glucose level, a 12-week administration of various apple polyphenols
at 600 mg/day improved the results of the oral glucose tolerance test (OGTT), showing
statistically significantly lower results in measurement after 30 min and the AUC of plasma
glucose concentration in OGTT than in the placebo group subjects [103]. According to the
results of a trial involving overweight adults with confirmed insulin resistance, a 6-week
supplementation of strawberry and cranberry polyphenol extracts of 333 mg/day had a
favorable impact on insulin sensitivity. In said study, the whole-body insulin sensitivity
was determined by the hyperinsulinemic–euglycemic clamp method, and statistically
significant improvement in insulin sensitivity was observed in the polyphenol treatment
group, although no beneficial changes in lipid profile, oxidative, and inflammatory markers
were confirmed [104]. Figure 5 below summarizes the effects of polyphenols on diabetes
outlined in this review.
Figure 5. Effects of polyphenols on diabetes in human studies.
6.3. Obesity
Influence on body composition parameters, blood lipids, and hormones regulating
energy intake are most common control parameters in clinical trials aimed at investigating
the anti-adiposity potential of polyphenols.
Body mass index (BMI), body fat percent, and abdominal circumference decreased in
overweight and obese adults over two months following an isocaloric diet and consuming
a daily dose of the extract of Hibiscus sabdarifa L. and Lippia citriodora L. containing 500 mg
phenolic compounds. Improvement in these anthropometric measurements was more
prominent in overweight than obese subjects and also significantly differed from the results
in the placebo group [105]. This same phenolic preparation was studied regarding its effect
on appetite regulation. The results revealed a decrease in the hunger-stimulating hormone
ghrelin, self-evaluated hunger sensation, and an increase in glucagon-like peptide-1 in
the treatment group [106]. In a trial conducted in Korea, anthropometric indicators were
evaluated after a 12-week intake of 900 mg/day citrus flavonoids containing preparation
Sinestrol-XPur. The overweight and obese adults in the intervention group had a statisti-
cally significant decrease in BMI and body fat mass compared to the controls [107]. A study
on healthy adults observed that a 10-day intake of a beverage containing 165 mg black
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tea polyphenols statistically significantly increased fecal lipid excretion in the treatment
versus placebo group, but did not cause any changes in the anthropometric parameters of
the study participants [108]. A double-blind, randomized trial confirmed beneficial effects
of bergamot juice flavonoid preparation of 650 mg or 1300 mg per day in the study group
of patients with metabolic syndrome. The 90-day long treatment was associated with
significant body weight and BMI reduction and beneficial changes in several parameters of
blood lipids such as decreased TC, TG, and atherogenic index of plasma [109]. Figure 6
below summarizes the outlined effects of polyphenols on obesity.
Figure 6. Effects of polyphenols on obesity in human studies.
6.4. Neurodegenerative Diseases
Antioxidant activity, anti-inflammatory, and neuroprotective properties of polyphe-
nols allow us to consider them as promising candidates in preventing and treating neurode-
generative diseases. Nevertheless, evidence is scarce on the neuroprotective or therapeutic
effects in human intervention trials.
Results in a comprehensive neurocognitive test did not show significant benefits from
the supplementation of a walnut-enriched diet (accounting for 15% of the daily energy
intake) on cognitive function in a large cohort of cognitively healthy seniors. Although
walnuts were chosen as the nuts richest in polyphenol, the two-year intervention did not
significantly improve global cognitive composite scores nor of specific cognitive domains
such as language or memory. However, higher effectiveness of the intervention was
observed in a subgroup of participants with lower education levels and lower background
status of dietary α-linolenic acid intake [110]. A pilot study reported results of a one-
year intake of 10 mg/day resveratrol in participants with mild to moderate Alzheimer’s
disease. Less deterioration of scores according to Alzheimer’s disease assessment scales
was found in the intervention group than in the control group, but none of the results were
statistically significant [111]. A multicenter trial conducted in Germany tested whether the
intake of epigallocatechin in an increasing dose of 400 to 1200 mg/d could modify disease
progression in multiple system atrophy patients. Results did not confirm a statistically
significant change in the motoric examination score of the Unified Multiple System Atrophy
Rating Scale after 48-week treatment compared with the placebo. A MRI sub-study of
disease-affected brain regions, however, indicated substantial lower annual striatal volume
loss in the intervention than in the placebo group [112]. Figure 7 below summarizes the
outlined effects of polyphenols on neurodegenerative diseases in humans.
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Figure 7. Effects of polyphenols on neurodegenerative diseases in human studies. Dashed lines
indicate a lack of significant results.
6.5. Digestive Disease
Several studies have reported the beneficial effects of curcumin supplementation
on patients with hepatic steatosis and NAFLD. In a randomized double-blind placebo-
controlled trial, patients with NAFLD were randomly assigned to receive an amorphous
dispersion curcumin formulation of 70-mg curcumin/day or placebo for a period of eight
weeks. Compared with the placebo, curcumin was associated with a significant reduction
in liver fat content (78.9% improvement in the curcumin vs 27.5% improvement in the
placebo group) as well as significant reductions in BMI and serum levels of TC, LDL-C,
triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated
hemoglobin [113]. In another study, fifty-eight NAFLD patients participated in a random-
ized, double-blind, placebo-controlled study. The subjects were allocated randomly into
two groups, receiving either a capsule of 250 mg phospholipid curcumin or placebo for a
period of eight weeks. Compared with the placebo, supplementation resulted in significant
decreases in serum levels of 3-methyl-2-oxovaleric acid, 3-hydroxyisobutyrate, kynure-
nine, succinate, citrate, α-ketoglutarate, methylamine, trimethylamine, hippurate, indoxyl
sulfate, chenodeoxycholic acid, taurocholic acid, and lithocholic acid [114]. Furthermore,
in another trial, where a total number of 80 patients were randomized to receive either
250 mg curcumin daily or the placebo for two months, the grade of hepatic steatosis, and
serum aspartate aminotransferase levels were significantly reduced in the treatment group
compared to the placebo [115].
Additionally, in a double-blind placebo controlled clinical trial of 102 patients with
liver steatosis, the intervention group receiving 300 mg/day of a nutraceutical containing
a bergamot polyphenol fraction and artichoke extract for 12 weeks presented a greater
reduction in liver fat content than the placebo group. The percentage CAP score reduction
was also statistically significant in those with android obesity, overweight/obesity as well
as in women. However, after adjustment for weight change, the percentage CAP score
reduction was statistically significant only in those over 50 years old [116].
Pediatric Crohn’s disease (CD) has been linked with higher thromboxane levels. On
this note, in a small-scale study with 14 children suffering from CD and 15 healthy con-
trols, the patients received polyphenolic extract pycnogenol to investigate the relationship
between polyphenols, thromboxane levels, and oxidative stress in children with Crohn´s
disease. At baseline, CD patients had significantly higher levels of the static and dy-
namic forms of thromboxane B2 in comparison to the controls. After 10 weeks, treatment
with pycnogenol decreased the level of the dynamic form of thromboxane B2, indicating
that pycnogenol administration may positively influence clinical symptoms of CD such
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as thromboembolic episodes [117]. In a large-scale study of 110 patients with CD (73%
women) and 244 patients with ulcerative colitis (57% women), 440 and 976 controls aged
20 to 80 years from eight countries were recruited between 1991 and 1998. During the
follow-up period of up to December 2010, the intake of flavones and resveratrol reduced
the risk of CD, although no significant associations were found for dietary polyphenol
intake and ulcerative colitis [118]. Figure 8 summarizes the effects of polyphenols on
digestive diseases seen in the outlined human studies.
Figure 8. Effects of polyphenols on digestive diseases in human studies. Dashed lines indicate lack of significant results.
6.6. Cancer
Several human experimental studies have been performed with the aim to prove the
potential of polyphenols as a preventive tool as part of combined treatment therapy to
attenuate the anticancer effect of conventional chemotherapeutics and as drugs to reduce
the side effects caused by chemotherapy. Polyphenols have been widely studied, and
anticancer effects are well explained in animal models and cell culture experiments. The
molecular mechanism of action of the experimental cell lines derived from specific cancer
cells could prove to be similar to the mechanisms in the human body as a whole. However,
the interpolation of results to humans should be done with caution due to the absence of
endogenous metabolism in cell models and the differences in gut microflora interaction
with polyphenols in animal studies [119].
6.6.1. Colorectal
The trial conducted by Sincrope et al. in a group of patients with colorectal adenoma or
cancer diagnosis did not prove the effect of 1200 mg daily green tea polyphenol preparation
containing 65% EGCG and 25% other catechins. There was no significant decrease in
adenoma recurrence rate and no reduction in percent of aberrant crypt foci, defined as
precursors of colorectal cancer in the study group comparing to the placebo group after
6-month treatment [120].
A multicenter study in Germany examined the effect of 3-year treatment of 300 mg per
day EGCG on colorectal adenoma incidence rate in patients after colorectal polypectomy.
The treatment group showed a slightly lower incidence rate than in the placebo group
though the difference was not statistically significant [121]. Intending to test whether the
effects of ellagitannins to modify colon gene expression observed in vitro could be repro-
duced in humans, the trial involved patients with malignant colon biopsy with 5–35 days
supplementation with ellagitannins and ellagic acid-containing pomegranate extract cap-
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sules. Analysis of particular colorectal cancer-related gene expression in malignant and
normal colon tissue after pomegranate extract treatment did not show changes concordant
to those observed in preclinical studies [122].
6.6.2. Prostate
A randomized controlled trial of prostate cancer prevention assessed the green tea
catechin metabolite plasma level and evaluated the changes in prostate-specific antigen
(PSA) in men with an increased risk of prostate cancer (PSA in the range between 2.0–
2.974 ng/mL or 2.974–19.95 ng/mL and negative biopsy). The green tea polyphenol
intake was measured either as intake by drinking at least three cups of green tea daily,
or by capsules containing 600 mg flavan-3-ol EGCG daily. At six months, EGCG plasma
concentration was significantly higher than baseline in both intervention groups, while
in the placebo group, changes were not detected. The PSA level, reported as one of the
secondary endpoints, did not differ between the active peroral intake and placebo groups
nor in each group compared to the baseline [123].
The therapeutic potential of muscadine grape skin supplement in prostate cancer
patients with biochemically recurrent (BRC) prostate cancer was studied in a randomized,
multicenter, placebo-controlled trial. Participants in both intervention groups received pow-
dered muscadine grape skin with the main phenolic component ellagic acid as preparation
MuscadinePlus in doses of 500 mg or 4000 mg daily for six to 12 months. The response to
the therapy was measured by changes in clinical markers—PSA level in blood plasma and
PSA doubling time (PSADT) with respect to individual PSADT calculated from PSA results
in a one year time period prior to enrollment in the trial. Decrease in PSA ≥50% of baseline
from trial and prolongation of PSADT resulting from therapy was defined as a clinically
significant effect of grape skin phenols as a treatment and would allow delaying androgen
deprivation hormonal therapy in men with BRC prostate cancer. Results did not confirm
statistically significant differences in the course of disease or increase in PSADT in any
group of MuscadinePlus doses compared with the placebo. Additional genetic analysis of
single nucleotide polymorphism (rs4880) of superoxide dismutase-2 gene revealed a more
significant increase in PSADT in high-dose MuscadinePlus patients with SOD2 Ala/Ala
genotype than patients in the control group [124].
6.6.3. Bladder
A randomized, double-blind, placebo-controlled study enrolled non-invasive urinary
bladder cancer patients before surgical treatment and studied the effects of the intake of
polyphenon E containing 800 mg or 1200 mg EGCG. Accumulation of EGCG in excised
bladder tissue was determined in a dose-response relationship in normal and malignant
tissue and could suggest that EGCG induces local biological activity in bladder tissue.
Analysis revealed statistically significant downregulation of two specific tissue biomarkers
of cellular proliferation–clusterin and proliferating cell nuclear antigen in both groups
of study participants after the 14 to 28 days course of polyphenon E intake. This pilot
study shows that EGCG has the potential for use as an anticarcinogenic agent in bladder
cancer [125].
6.6.4. Side Effects of Anticancer Therapy
The potential of topically administered silymarin flavonolignans to prevent the de-
velopment of radiodermatitis as a complication of radiotherapy was tested in a trial with
breast cancer patients. Study results showed that a three week application of silymarin gel
on the skin of the chest wall delayed the development of radiodermatitis and decreased
its severity compared to results in the placebo group [126]. These beneficial effects of
silymarin were also observed in patients with gastrointestinal cancer. After nine weeks
of application of silymarin gel, the frequency of severe hand-foot syndrome cases caused
by the chemotherapy drug capecitabine was statistically lower in the intervention group
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compared to the placebo [127]. Figure 9 summarizes the effects of polyphenols on cancer
seen in the outlined human studies.
Figure 9. Effects of polyphenols on cancer in human studies. Dashed lines indicate a lack of significant
results.
7. Conclusions
Based on the data collected in this review, we can conclude that various plants in our
diet contain phenolic compounds that have pharmacological activities against diseases such
as cardiovascular, digestive, and neurodegenerative disease, diabetes, obesity, and cancer.
In vitro studies showed clear and specific mechanisms of action when the polyphenol was
used in its pure form and at high concentrations compared to when ingested through
foods rich in these polyphenols. The same was observed when treatments were carried
out on experimental animals. In humans, the mechanisms of action are more complicated
to obtain, although favorable biochemical and physiological parameters were observed
against some of the pathologies studied when pure polyphenol extracts or aliments rich
in these polyphenols are administered. These effects in vitro, in animals and humans are
all outlined in Figure 10 below. Nonetheless, the bioavailability that they present when
we eat foods with these compounds is low, as, although their absorption is high in their
free form, our detoxification system is in charge of eliminating them, and does so very
effectively. This, however, does not mean that they do not have favorable or preventive
effects against different pathologies. Therefore, based on these data, the intake of foods
rich in polyphenols could be advised in order to prevent diseases and as concomitant
treatments accompanying pharmacological drugs. However, the usage of high doses of the
isolated compounds in humans have not yet been indicated, and therefore further clinical
trials are necessary to specify recommended doses.
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Figure 10. Summary of the effects of polyphenols in animal models, human studies, and in vitro.
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Abbreviations
AFAB2 adipocyte fatty acid binding protein 2
AKT protein kinase B
BB Davallia formosana
BP blood pressure





FOXO1 forkhead box protein O 1
IR insulin resistance
LDL-C low-density lipoprotein cholesterol
NAFLD nonalcoholic fatty liver diseases
OGTT oral glucose tolerance test
PI3K phosphatidylinositol 3-kinase
PPARγ peroxisome proliferator-activated receptor gamma
PSA prostate-specific antigen
PSADT PSA doubling time
SREBP1c sterol regulatory element-binding protein 1
T2DM type 2 diabetes mellitus
TAS total antioxidant status
TC total cholesterol
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